key: cord-0977028-yx5nou47
authors: Chow, Karin; Aslam, Anoshe; McClure, Tara; Singh, Jessica; Burns, Jacquelyn; McMillen, Tracy; Jani, Krupa; Lucca, Anabella; Bubb, Tania; Robilotti, Elizabeth V; Babady, N Esther; Kamboj, Mini
title: Risk of Healthcare-Associated Transmission of SARS-CoV-2 in Hospitalized Cancer Patients
date: 2021-07-30
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab670
sha: e875740e946b58f7b302a716c9277102df9eb037
doc_id: 977028
cord_uid: yx5nou47

BACKGROUND: There is limited information on the risk of hospital-acquired COVID-19 among high-risk hospitalized patients after exposure to an infected patient or healthcare worker (HCW) in a non-outbreak setting. METHODS: This study was conducted at a tertiary care cancer center in New York City from March 10, 2020, until February 28, 2021. In early April 2020, the study institution implemented universal SARS-CoV-2 testing at admission and retesting every three days through the hospital stay. Contact tracing records were reviewed for all exposures to SARS-CoV-2 positive patients and HCWs. RESULTS: From March 10, 2020, to February 28, 2021, 11,348 unique patients who were SARS-CoV-2 PCR negative at the time of admission underwent 31,662 post-admission tests during their hospitalization, and 112 tested positive (0.98%). Among these, 49 patients housed in semi-private rooms during admission resulted in 74 close contacts and 14 secondary infections within 14 days, for an overall attack rate of 18.9%. Among those exposed to a roommate undergoing an aerosol-generating procedure (AGP), the attack rate was 35.7%. WGS corroborated transmission in 6/8 evaluated pairs. In addition, three transmission events occurred in 214 patients with significant exposure to 105 COVID-19 positive healthcare workers (1.4%). CONCLUSION: The overall risk of hospital-acquired COVID-19 is low for hospitalized cancer patients, even during periods of high community prevalence. However, shared occupancy with an unrecognized case is associated with a high secondary attack rate in exposed roommates.

Since SARS-CoV-2 infection was first reported in the United States, several coronavirus disease 2019 (COVID- 19) outbreaks have been reported in acute care settings (1,2).

Universal testing for SARS-CoV-2 at the time of hospital admission is a recommended strategy to prevent nosocomial SARS-CoV-2 infection when the community prevalence is high. However, individuals early in the infection course may not have a detectable virus, and false-negative results may occur due to analytic reasons or poor sampling technique (3) . Late detection of SARS-CoV-2 in hospitalized patients has been described as the source of several reported outbreaks. Overall, for patients admitted to an acute care setting, the risk of SARS-CoV-2 transmission from other patients or infected healthcare workers is rarely described in a non-outbreak setting (4) (5) (6) (7) .

New York City confirmed its first case of COVID-19 on March 1, 2020. The first wave of the epidemic peaked in mid-April, followed by sustained low case counts until October 1, 2020.

A second surge soon followed with a peak in January 2021 (8) . As part of the nosocomial risk mitigation strategy, the study institution implemented serial testing of all hospitalized patients every three days until discharge and regardless of COVID-19 symptoms. We also recommended biweekly asymptomatic healthcare worker (HCW) testing in inpatient and procedural settings.

This report characterizes the risk of SARS-CoV-2 acquisition in hospitalized cancer patients after direct contact with an infected patient or healthcare worker. 

Memorial Sloan Kettering Cancer Center (MSKCC) is a 514-bed tertiary care cancer center with 22,417 annual admissions and 160,298 inpatient days in 2020. 57 % of beds are in shared occupancy. On March 10, 2020 polymerase chain reaction (PCR) testing for SARS-CoV-2 was made available for patients. Starting on April 6, all patients admitted to MSKCC were tested on admission, and starting on April 13 all hospitalized patients with an initial negative test were routinely retested every 3 days through their hospital stay.

Patients with confirmed SARS-CoV-2 were transferred to designated COVID-19 units and placed in private rooms under Airborne-Contact isolation. In the event of an exposure to a confirmed case of SARS-CoV-2 in a patient or HCW, contact tracing was done for all patients. As per CDC guidelines, significant exposure was defined as being within 6 feet of an infected person for at least 15 minutes (9). The exposure period was defined as two days before symptom onset or two days before positive PCR specimen collection if index case was asymptomatic. Exposed roommates of a positive case were placed on droplet precautions for 14 days from last exposure, with the last follow up date on February 28, 2021. Prior to routine retesting of all hospitalized patients, post-exposure testing was done 5 and 12 days after last contact. All inpatients exposed to an infected HCW were also placed on droplet precautions and postdischarge quarantine for 14 days. Duration of interaction, healthcare worker role, and personal protective equipment (PPE) were assessed for all other staff exposures. Quarantined patients followed the same testing schedule outlined above.

A c c e p t e d M a n u s c r i p t 6 Universal masking for all healthcare workers was introduced on March 20, 2020, followed by universal face shields on April 22, 2020. Starting April 11, all patients were required to wear a face mask during their visit at the study institution. Masking for inpatients was implemented on December 21, 2020. N95 respirators and face shields were required for healthcare workers for all AGPs. For AGPs in shared rooms, the curtains are drawn, all shared equipment is moved from the immediate vicinity, and the roommate dons a surgical mask.

Testing for SARS-CoV-2 RNA was performed on nasopharyngeal swabs (NPS) or saliva samples. SARS-CoV-2 RNA was detected using either a laboratory-developed test based on the CDC protocol, the Xpert Xpress SARS-CoV-2 test (Cepheid, Sunnyvale, California), the 

Among 112 patients with first positive test on post-admission testing, 49 had been housed in semi-private rooms before the diagnosis (Median = 3 days, 1-34). This resulted in 74 close contact exposures in their roommates, 14 of whom eventually tested positive within two weeks. As shown in Figure 1A , secondary transmission after exposure to newly positive inpatients was primarily identified during NYC surge periods (93%), and the overall secondary attack rate among exposed roommates was 18.9% (Table 1, Figure 1B remained asymptomatic, 16 deemed as pre-symptomatic, and 6 reported symptoms on date of surveillance test. 60 roommates exposed to 41 unique COVID-19 positive index cases did not develop an infection. Collectively, 152 tests were done on the 74 exposed roommates in the 14-day monitoring period.

The median time to infection from index case diagnosis in exposed persons was three days (Range 1-12 days). The exposures for these cases were from 9 symptomatic and 4 asymptomatic index cases. The mean Ct value for target 1 in index patients with no A c c e p t e d M a n u s c r i p t 9 secondary transmission and those with transmission was 28.62 ± 9.20 (SD) and 23.12 ± 8.09

(SD), respectively (t = 1.88, p = 0.07). There were 4 index cases with Ct value > 30 with secondary transmission to roommates (Figure 3) . Secondary cases had similar room overlap with index cases (IQR 39 hours) compared to close contact who did not convert (IQR 37 hours) ( Figure 1B) .

Of 74 total roommates, 14 were exposed to AGPs performed prior to the index case testing positive for COVID-19. 5 of 14 patients exposed to AGPs developed infection during the 14day monitoring period (35.71%) ( Table 2 ). Out of 27 index and secondary cases, whole genome sequencing was done for 22 stored samples that evaluated 8 complete epidemiologically linked pairs (index and roommate). WGS corroborated transmission from the index case in 6/8 infections diagnosed among exposed roommates as shown in Table 3 , Figure 4 , and Figure 5 . For two pairs with SNP differences ≥2, one was possibly community acquired ten days after discharge, and eleven days from last exposure to the index case (Pair 2I, 2R2). The probable alternate source of transmission for the other case remains unrecognized (Pair 11I, 11R).

During the study period, more than 17,000 employees across the study institution were tested, index cases included 1 nurse and 2 nursing support staff; all three were symptomatic. In one event the patient was exposed the day before the nurse's symptom onset during two vitals assessments lasting < 10 minutes. Exposures to the two nursing support staff occurred within 2 days after their symptom onset and included brief interactions to assess patient intake and output during the day, lasting < 10 minutes. Two pairs were excluded from WGS due to low viral load, while Pair 16 ( Figure 5, Table 3 ) was typed as different lineages with a SNP difference of 9 between the HCW-patient strain. Overall, among the 6 suspected transmission events (1.12%), the median time to detection in patients after last HCW interaction was 5 days (Range 1-11 days) and WGS corroborated 2/3 evaluated patient conversions.

This study describes an overall low SARS-CoV-2 nosocomial risk during hospitalization despite two distinct regional surges of widespread SARS-CoV-2 community transmission.

Most cases of nosocomial infection occurred when community prevalence rates were high (10) (11) (12) . High secondary attack rates were observed among those in shared occupancy with an unrecognized case, especially after exposure to AGPs. This clinical scenario merits strong consideration for the routine application of post-exposure prophylactic use of monoclonal antibodies among highly vulnerable patients.

Of 49 infected index cases, 45 tested positive within 14 days of admission with a median of 3 days. Given the median incubation period of COVID-19 is 4-5 days, index cases primarily represented patients exposed in the community. False negative results are possible with SARS-CoV-2 PCR testing due to early undetectable viral loads or sampling technique (3).

Among 74 close contact exposures in the present study, 14 secondary cases were detected, 75 % of evaluated pairs were corroborated by WGS. The mean Ct of all index cases was 27.06 ± 9.16, with a median shared room duration of fewer than two days with the index case, and A c c e p t e d M a n u s c r i p t 11 was not significantly different between source patients with and without secondary transmission. One potential reason for this observation is that contact tracing was based on the first detection of PCR confirmed COVID-19, however the overall risk of hospitalacquired COVID-19 might have been influenced by the transmissibility of the source case.

The likelihood of intermittent RNA shedding post-acute infection that is incidentally detected on routine surveillance is one potential explanation for the lack of observed transmission.

Studies have found a lower secondary clinical attack rate more than five days from symptom onset (13, 14) , and prolonged PCR positivity is common in cancer patients (15, 16) .

Regarding high secondary attack with AGPs, prior literature on aerosol transmission comes from the 2003 SARS-CoV pandemic (17, 18) , and the description of risk in COVID-19 transmission remains limited to case studies (19, 20) . Our study also found a low attack rate from HCWs to patients in the inpatient setting even during close and prolonged contact (1.12%), consistent with observations from other facilities (21) .

The risk of acquiring COVID-19 increases with the amount of contact with infected individuals. The most intense exposure between patients or between patients and providers occurs during hospitalization for acute care. Despite the universal adoption of comprehensive testing and PPE practices, several hospital-based COVID-19 outbreaks were reported last

year. The pandemic has also caused uncertainty and fear in cancer patients with frequent healthcare-related exposure, with several interrupting their care due to the fear of acquiring COVID-19 and devastating consequences on the overall prognosis. The general secondary attack of SARS-CoV-2 in published studies from healthcare settings is estimated to be around 0.7% (13) . However, this risk is not stratified by the type of exposure within the acute care setting, with most studies describing secondary attack rates in HCW exposed to infected patients.

A c c e p t e d M a n u s c r i p t 12 The availability of highly effective vaccines dramatically reduces the risk of COVID-19 infection and will likely have a considerable impact on nosocomial risk. However, there is still limited experience with vaccine effectiveness in real-world conditions, specifically in cancer patients in whom the vaccine-induced protection may be blunted. The practice of surveillance testing as a risk mitigation strategy is still being followed at many places as community rates decline, and especially among specific high-risk populations with limited protection from the vaccine. Our data shows risk of secondary transmission to be low, and the small number of cases occurred only during surge periods, with 13 of 14 secondary infections occurring from March-May 2020 or December 2020-Feburary 2021. This suggests that enhanced test-based surveillance of asymptomatic patients is unnecessary even in highly susceptible populations when the overall community risk is low, conserving testing resources and reducing patient burden from repeat testing.

Although collectively our study findings provide reassurance on the low risk of nosocomial acquisition, additional strategies may be needed further to reduce the risk to patients in shared occupancy. Post-exposure prophylaxis with monoclonal antibodies is a promising strategy that has proven beneficial among exposed household contacts or nursing home residents (22, 23) and FDA should strongly consider authorizing its use in the hospital setting with comparable attack rates to those observed after household exposures.

Our study has several limitations. First, patients discharged during the monitoring period were only tested if they reported new symptoms, potentially missing asymptomatic infections diagnosed in the outpatient or other setting. Second, contact investigations were based on documented symptom onset or first positive test. Third, not all paired samples were available for WGS to confirm transmission events although the majority that were evaluated revealed no SNP differences. Finally, the impact of COVID-19 vaccination in patients and healthcare workers is not measured as the study dates preceded broad dissemination of vaccines. M a n u s c r i p t 13 In summary, this report demonstrates an overall low risk of hospital-acquired COVID-19 among immunocompromised patients even during high SARS-CoV-2 community prevalence.

However, post-exposure prophylaxis should be considered for patients in shared occupancy after exposure to an infected hospital roommate. In addition, despite the uncertain vaccine effectiveness in cancer patients, routine testing of asymptomatic patients in oncology settings is unnecessary when the community rates are low. M a n u s c r i p t 18 Tables   Table 1: Post-exposure secondary attack rate in patients after exposure to an infected HCW or roommate.

No transmission 528 (98.88%) 60 (81.08%) Secondary infection 6 (1.12%) 14 (18.92%)

M a n u s c r i p t 

A SARS-CoV-2 Cluster in an Acute Care Hospital

Surveillance and identification of clusters of healthcare workers with coronavirus disease 2019 (COVID-19): Multidimensional interventions at a comprehensive cancer center

Overview of Testing for SARS-CoV-2

Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission

Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan

Incidence of Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center

Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong

New York City Department of Health COVID-19 Data

Variations in US hosptial mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic

Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66

Hospital-acquired Cases in a London Teaching Hospital

SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in

Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset

Serial interval of novel coronavirus (COVID-19) infections

Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon

Duration of Viral Shedding of Discharged Patients With Severe COVID-19

procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong

Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient

Low Risk of Coronavirus Disease 2019 (COVID-19) Among Patients Exposed to Infected Healthcare Workers

Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)

19-morbidity-and-mortality-in-nursing-home-setting

M a n u s c r i p t A c c e p t e d M a n u s c r i p t 20